Article Text

other Versions

PDF

Journal club
Dupilumab in persistent asthma with elevated eosinophil levels
  1. Ruksha Bhadresha
  1. Correspondence to Dr Ruksha Bhadresha, FY2 East Sussex Healthcare NHS Trust, Conquest Hospital, The Ridge, St Leonards-on-Sea, East Sussex TN37 7RD, UK; ruksha.bhadresha{at}nhs.net

Statistics from Altmetric.com

Monoclonal antibodies are an effective treatment for a number of inflammatory autoimmune conditions, particularly those refractory to first-line medications. In asthma, airway inflammation may be associated with Th2 cell overactivity and raised eosinophils in up to 50% of cases. Th2 activation leads to the release of interleukin (IL)-13 and IL-4, which mediate their effects via receptors containing the IL-4 α subunit. Dupilumab is an IL-4 α subunit inhibitor aiming to block both signalling pathways and reduce airway inflammation.

The authors conducted a randomised, double-blind, placebo-controlled study to evaluate the effectiveness and safety of dupilumab in the treatment of persistent moderate-to-severe asthma. They recruited 104 patients, aged 18–65, who had an elevated blood or sputum eosinophil count and symptoms that remained poorly controlled despite medium-dose to high-dose inhaled corticosteroid (ICS) and long-acting bronchodilators (LABAs). Patients received once-weekly subcutaneous injections of dupilumab or placebo for 12 weeks or until they suffered an asthma exacerbation. LABAs were discontinued at week 4, and ICSs tapered from week 6 to stop by week 9.

The primary outcome was an asthma exacerbation requiring systemic steroids or hospital attendance. This was seen in 6% of those receiving dupilumab and 44% of those receiving placebo. In terms of secondary outcomes, dupilumab patients showed significant improvements in FEV1, morning peak respiratory flow rate, asthma symptoms, nocturnal awakening, salbutamol use and Th2-associated inflammatory markers.

These promising results warrant further investigation over a longer time frame. Adverse effects, notably injection-site reactions, nasopharyngitis, nausea and headache, were reported more frequently with dupilumab; hence, further studies are required to determine its long-term safety and side-effect profile, something that may ultimately affect patient compliance.

▸ Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455–66.

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.